MYC and neoplasm: In CRC and HCC cell lines, FZC18 decreases the protein levels of total and non-phosphorylated β−catenin and downstream targets, such as cyclin D1 and c-myc. These findings are associated with ∼60% to 70% reduction of tumor cell growth and ∼25% induction of cell death.